Results 111 to 120 of about 4,937 (255)

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Acantholytic plaque on the right breast. [PDF]

JAAD Case Rep
McKenzie TT, White R, McNish A, Smith-Matthews S, Ho JD.   +4 more
europepmc   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Synchronous Ectopic Adrenal Rhabdomyosarcoma and Ipsilateral Cystic Nephroma Revealing a Diagnosis of DICER1-Related Tumor Predisposition: A Case Report. [PDF]

Case Rep Surg
Chara AO, Gupta VS, Liang J, Borinstein SC, Benedetti DJ, Shelton J.   +5 more
europepmc   +1 more source

Histiocytosis development and clinical variation through the lens of genomics

The Journal of Pathology, Volume 270, Issue 1, Page 23-39, September 2026.
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps, Astrid GS van Halteren, Tom van Wezel, Pancras CW Hogendoorn   +3 more
wiley   +1 more source

Wilms Tumor with Inferior Vena Cava Thrombus: Comparative Analysis of Clinical Characteristics and Outcomes. [PDF]

Curr Oncol
Al-Hasan R, Al-Qawabah R, Ghandour K, Ibrahimi AK, Sarhan N, Sultan I, Halalsheh H.   +6 more
europepmc   +1 more source

Exploring Neutrophil Extracellular Traps in Canine Soft Tissue Sarcomas: A Preliminary Study With Translational Insights

Veterinary Medicine and Science, Volume 12, Issue 5, September 2026.
Neutrophil Extracellular Traps (NETs) in Canine Soft Tissue Sarcomas This study investigated the presence of neutrophil extracellular traps (NETs) in canine soft tissue sarcomas using dual immunohistochemistry for citrullinated histone‐3 and myeloperoxidase.
Burak Yildirim, Volkan Ipek
wiley   +1 more source

Adult Wilms Tumour: A Case Report of an Atypical Presentation and Literature Review. [PDF]

Cureus
Gil M, Cabrita Carneiro J, Cabral Pimentel J, Meireles A, Campos Pinheiro L.   +4 more
europepmc   +1 more source

Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods

Brain Pathology, Volume 36, Issue 5, September 2026.
This study characterizes the molecular subgroup–specific features of a nationwide Japanese cohort comprising 242 medulloblastomas (MBs). Furthermore, we introduce SEE‐6‐CNA, a simple, cost‐effective, and FFPE‐compatible molecular test that is applicable to routine pathology samples and serves as a surrogate for risk stratification in non‐WNT/non‐SHH ...
Kohichi Go, Asako Katsuma, Ema Yoshioka, Tomoko Shofuda, Kohei Fukuoka, Koichi Ichimura, Yuko Matsushita, Yohei Mineharu, Yasuhide Makino, Takeshi Kawauchi, Atsushi Sasaki, Junko Hirato, Takeshi Inoue, Yoshinori Kodama, Masayuki Mano, Daisuke Kanematsu, Noriyuki Kijima, Naoki Kagawa, Dai Keino, Akitake Mukasa, Tomonari Suzuki, Koji Yoshimoto, Daisuke Kuga, Keishi Horiguchi, Shigeru Yamaguchi, Masayuki Kanamori, Kai Yamasaki, Kenichi Ishibashi, Takuya Akai, Masayoshi Yamaoka, Ryuji Ishizaki, Atsufumi Kawamura, Shigeo Ohba, Joji Ishida, Ryo Ando, Junya Fukai, Tomoru Miwa, Masazumi Fujii, Ai Muroi, Kuniaki Saito, Atsuko Harada, Yasuhiko Hayashi, Masahiro Nonaka, Young‐Soo Park, Yusuke Kobayashi, Tadashi Higuchi, Yosuke Miyairi, Kazuhisa Yoshifuji, Noriyoshi Takebe, Soichi Oya, Kosuke Nakajo, Mitsutoshi Nakada, Yoshiteru Nakano, Mizuki Kambara, Koji Adachi, Kazuhiro Tanaka, Hideo Nakamura, Yukihiko Sonoda, Ryuta Saito, Takafumi Wataya, Kazuhiko Kurozumi, Michael D. Taylor, Yoshitaka Narita, Soichiro Shibui, Hajime Arai, Hiroaki Sakamoto, Isao Date, Motoo Nagane, Ryo Nishikawa, Yoshiki Arakawa, Yonehiro Kanemura   +70 more
wiley   +1 more source